■目前的文献广泛地涵盖了使用蝶腭神经节刺激(SPGs)治疗广泛的医疗条件,如过敏性鼻炎,丛集性头痛,和中风。然而,在这些研究的系统组织和分析方面存在明显的差距。本文旨在通过对各种医疗条件下的SPG的现有文献进行全面回顾和分析来弥合这一差距。
■这项研究通过在PubMed上进行的系统的计算机化搜索,精心构建了一个全面的数据库,Embase,CNKI,万方,VIP,和CBM至2022年5月。纳入标准包括以中文或英文发表的随机对照试验(RCT),专注于SPG在各种医疗条件下的治疗应用。定性和定量结果指标均被认为符合纳入条件。
■这项综合研究回顾了36种出版物,包括10个高质量的,23中等质量,和三篇低质量的文章。这项研究调查了各种疾病,包括过敏性鼻炎(AR),缺血性中风(IS),丛集性头痛(CH),原发性三叉神经痛(PTN),小儿慢性分泌性中耳炎(PCSO),顽固性面瘫(RFP),慢性紧张型头痛(CTTH),以及慢性丛集性头痛(CCH)中低频蝶腭神经节刺激(LF-SPGs)的分析以及SPGs对正常鼻腔功能(NNCF)的影响。SPG显示出治疗AR的功效。关于改善鼻结膜炎生活质量问卷(RQLQ)评分,根据SUCRA排名,SPG被认为是最佳干预措施。关于总鼻部症状评分(TNSS)的改善,传统针灸与传统中药(CA-TCM)在SUCRA排名中具有显着优势,被认为是最佳干预措施。就提高有效利率(ER)而言,SPG优于常规针灸(CA)和西药(WM;P<0.05)。在对IS进行SPG治疗的背景下,结果表明,3个月的结果有了显着改善,如改良Rankin量表(mRS)在脑梗死(CCI;P<0.05)的情况下进行评估。在用SPGs治疗CH时,该治疗对头痛的缓解和消失有统计学意义(P<0.05)。SPG对NNCF的影响显示鼻气道阻力(NAR)有统计学意义的改善(P<0.05),鼻腔容积(NCV),呼出一氧化氮(eNO),P物质(SP),血管活性肠肽(VIP)和神经肽Y(NPY)。PCSO的SPGs治疗,RFP,和CTTH,与对照组相比,结果具有统计学意义(P<0.05)。
■SPG在AR的治疗中显示出显著的有效性,IS,和CH。CCH的有效管理可能需要同时解决自主神经失调和更深的神经通路。然而,额外的高质量研究对于阐明其对NNCF的影响至关重要,PTN,PCSO,RFP,和CTTH。
■PROSPERO,标识符CRD42021252073,https://www.crd.约克。AC.uk/PROSPERO/display_record。php?RecordID=312429。
UNASSIGNED: Current literature extensively covers the use of sphenopalatine ganglion stimulation (SPGs) in treating a broad spectrum of medical conditions, such as allergic rhinitis, cluster headaches, and strokes. Nevertheless, a discernible gap in the systematic organization and analysis of these studies is evident. This paper aims to bridge this gap by conducting a comprehensive review and analysis of existing literature on SPGs across various medical conditions.
UNASSIGNED: This study meticulously constructed a comprehensive database through systematic computerized searches conducted on PubMed, Embase, CNKI, Wanfang, VIP, and CBM up to May 2022. The inclusion criteria encompassed randomized controlled trials (RCTs) published in either Chinese or English, focusing on the therapeutic applications of SPGs for various medical conditions. Both qualitative and quantitative outcome indicators were considered eligible for inclusion.
UNASSIGNED: This comprehensive study reviewed 36 publications, comprising 10 high-quality, 23 medium-quality, and three low-quality articles. The study investigated various diseases, including allergic rhinitis (AR), ischemic strokes (IS), cluster headache (CH), primary trigeminal neuralgia (PTN), pediatric chronic secretory otitis (PCSO), refractory facial paralysis (RFP), chronic tension-type headache (CTTH), as well as the analysis of low-frequency sphenopalatine ganglion stimulation (LF-SPGs) in chronic cluster headache (CCH) and the impact of SPGs on Normal nasal cavity function (NNCF). SPGs demonstrate efficacy in the treatment of AR. Regarding the improvement of rhinoconjunctivitis quality of life questionnaire (RQLQ) scores, SPGs are considered the optimal intervention according to the SUCRA ranking. Concerning the improvement in Total Nasal Symptom Score (TNSS), Conventional Acupuncture Combined with Tradiational Chinese Medicine (CA-TCM) holds a significant advantage in the SUCRA ranking and is deemed the best intervention. In terms of increasing Effective Rate (ER), SPGs outperformed both conventional acupuncture (CA) and Western Medicine (WM; P < 0.05). In the context of SPGs treatment for IS, the results indicate a significant improvement in the 3-month outcomes, as evaluated by the modified Rankin Scale (mRS) in the context of Cerebral Cortical Infarction (CCI; P < 0.05). In the treatment of CH with SPGs, the treatment has been shown to have a statistically significant effect on the relief and disappearance of headaches (P < 0.05). The impact of SPGs on NNCF reveals statistically significant improvements (P < 0.05) in nasal airway resistance (NAR), nasal cavity volume (NCV), exhaled nitric oxide (eNO), substance P (SP), vasoactive intestinal peptide (VIP) and neuropeptide Y (NPY). SPGs treatments for PCSO, RFP, and CTTH, when compared to control groups, yielded statistically significant results (P < 0.05).
UNASSIGNED: SPGs demonstrate significant effectiveness in the treatment of AR, IS, and CH. Effective management of CCH may require addressing both autonomic dysregulation and deeper neural pathways. However, additional high-quality research is essential to clarify its effects on NNCF, PTN, PCSO, RFP, and CTTH.
UNASSIGNED: PROSPERO, identifier CRD42021252073, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=312429.